```html

Kernicterus (Severe Jaundice)

What is Kernicterus (Severe Jaundice)?

Kernicterus is a rare but serious form of brain damage that occurs when very high levels of bilirubin accumulate in a newborn’s bloodstream and cross the blood‑brain barrier. Bilirubin is a yellow pigment produced during the normal breakdown of red blood cells. In most infants, the liver converts bilirubin into a form that can be excreted in stool and urine, causing the common, usually benign condition known as physiologic jaundice. When the liver can’t keep up, bilirubin levels rise, leading to jaundice. If untreated, bilirubin can reach neurotoxic concentrations (>20 mg/dL) and deposit in the basal ganglia, brainstem nuclei, and cerebellum – the hallmark of kernicterus.

Historically, kernicterus was a leading cause of infant mortality, but early detection and phototherapy have dramatically reduced its incidence in developed countries. Nevertheless, it remains a critical public‑health concern in low‑resource settings and among infants with underlying risk factors.

Common Causes

Any condition that markedly increases bilirubin production, decreases bilirubin conjugation, or impairs bilirubin excretion can precipitate severe jaundice and potentially kernicterus. The most frequent contributors are:

• Hemolytic disease of the newborn (HDN) – maternal–fetal blood type incompatibility (e.g., ABO or Rh).
• G6PD deficiency – an inherited enzyme defect causing red‑cell fragility.
• Hereditary spherocytosis – abnormal red‑cell membranes that increase hemolysis.
• Crigler‑Najjar syndrome type I – a rare genetic absence of the enzyme UDP‑glucuronosyltransferase.
• Breast‑feeding jaundice – inadequate milk intake during the first 48‑72 hours leading to dehydration and reduced bilirubin clearance.
• Breast‑feeding associated jaundice – prolonged breastfeeding with suboptimal caloric intake after day 3–5.
• Neonatal sepsis – infection can impair hepatic function and increase hemolysis.
• Prematurity – immature liver enzymes and a higher proportion of fetal hemoglobin.
• Congenital hypothyroidism – slows bilirubin metabolism.
• Medications that displace bilirubin – e.g., sulfonamides, ceftriaxone, or certain antibiotics.

While each cause is distinct, the underlying theme is a rapid rise in unconjugated bilirubin that overwhelms the newborn’s limited detoxification capacity.

Associated Symptoms

Early jaundice is often subtle, appearing as a yellow tint to the skin and sclera. As bilirubin levels climb, additional signs may develop:

• Feeding difficulty or poor weight gain.
• Lethargy, excessive sleepiness, or difficulty waking.
• High‑pitched crying or irritability.
• Hypotonia (floppy‑baby appearance) or, paradoxically, hypertonia (muscle stiffness).
• Seizures – especially in late‑stage kernicterus.
• Hearing loss, auditory neuropathy.
• Movement disorders (chorea, athetosis) that may emerge months after the acute phase.
• Developmental delay, cerebral palsy‑like features.

These neurologic manifestations result from bilirubin toxicity in the basal ganglia and brainstem, hence the term “kernicterus” (“kerni” = nucleus, “icterus” = jaundice).

When to See a Doctor

Because bilirubin can rise quickly, prompt evaluation is essential. Contact a pediatrician or go to the emergency department if you notice any of the following:

• Visible jaundice in the face, chest, or thighs of a newborn < 24 hours old.
• Jaundice persisting beyond 14 days in a term infant or beyond 7 days in a preterm infant.
• Feeding problems, vomiting, or failure to gain weight.
• Excessive sleepiness, difficulty waking, or a high‑pitched cry.
• Any sign of dehydration (dry mouth, fewer wet diapers).
• Family history of hemolytic disease, G6PD deficiency, or liver disorders.

Early medical attention can prevent bilirubin from reaching neurotoxic levels.

Diagnosis

Evaluation combines a careful clinical exam with laboratory and imaging studies:

1. Physical Examination

• Assessment of jaundice distribution (head → trunk → extremities) to estimate bilirubin load.
• Neurologic exam for tone abnormalities, reflex changes, or seizures.

2. Laboratory Tests

• Serum total bilirubin (TB) and direct bilirubin – the primary metric; levels >20 mg/dL in term infants are high‑risk.
• Complete blood count (CBC) and reticulocyte count – to detect hemolysis.
• Blood type and Coombs test – to assess maternal‑fetal incompatibility.
• G6PD screening if hemolysis is suspected.
• Liver function panel – to rule out hepatic dysfunction.
• Blood culture if sepsis is a concern.

3. Imaging & Ancillary Tests

• Transcranial ultrasound – may show kernicterus‑related echogenicity in the basal ganglia.
• Brain MRI (rarely needed) – can detect bilirubin deposition as hyperintense signals on T1‑weighted images.
• Auditory brainstem response (ABR) testing – baseline hearing assessment, since kernicterus can cause permanent hearing loss.

4. Risk‑Stratification Tools

Clinicians often use the American Academy of Pediatrics (AAP) bilirubin nomograms or the WHO treatment guidelines to decide on phototherapy or exchange transfusion thresholds.

Treatment Options

The goal is rapid reduction of serum bilirubin to non‑toxic levels while addressing the underlying cause.

1. Phototherapy

• First‑line therapy for most infants with bilirubin >15 mg/dL (term) or lower thresholds for preterm.
• Blue‑green light (≈460 nm) converts bilirubin into water‑soluble isomers that are excreted without conjugation.
• Intermittent or continuous exposure for 6–24 hours, depending on response.
• Close monitoring of bilirubin levels every 4–6 hours.

2. Exchange Transfusion

• Reserved for bilirubin levels >30 mg/dL, rapid rise (>0.5 mg/dL/hr), or signs of impending neurologic injury.
• Procedure replaces the infant’s blood with donor blood, halving the bilirubin load.
• Requires central venous access and experienced staff; carries risks (electrolyte shifts, infection).

3. Intravenous Immunoglobulin (IVIG)

• Useful in hemolytic disease of the newborn due to ABO or Rh incompatibility.
• IVIG blocks Fc receptors, reducing hemolysis and the bilirubin surge.

4. Treat Underlying Causes

• For G6PD deficiency – avoid oxidative stressors (certain drugs, fava beans).
• Antibiotics for sepsis.
• Thyroid hormone replacement if congenital hypothyroidism is diagnosed.

5. Supportive Home Care (after stabilization)

• Frequent feedings (every 2–3 hours) to promote gut motility and bilirubin excretion.
• Maintain adequate hydration; monitor urine output and wet diapers.
• Follow‑up bilirubin checks as directed by the pediatrician.

Prevention Tips

While some risk factors (genetics, prematurity) cannot be changed, many strategies reduce the chance of severe jaundice:

• Early and adequate breastfeeding – Initiate within the first hour of life; aim for 8–12 feedings/day.
• Educate mothers on proper latch and feeding cues.
• Monitor weight and diaper output during the first week.
• Universal newborn bilirubin screening at 24 hours (or earlier for high‑risk infants).
• For mothers with known blood‑type incompatibility, give prophylactic anti‑D immunoglobulin (Rh‑negative mothers) and consider early phototherapy.
• Avoid medications that displace bilirubin in newborns (e.g., sulfonamides, certain cephalosporins).
• Prompt treatment of any infection or metabolic disorder in the neonate.
• Genetic counseling for families with known hereditary hemolytic disorders.

Emergency Warning Signs

Key Take‑aways

Kernicterus is preventable with timely detection and treatment of severe newborn jaundice. Parents should be vigilant for yellow discoloration, feeding problems, and changes in alertness. Early phototherapy dramatically reduces the risk of irreversible brain injury, and in rare, extreme cases, exchange transfusion can be lifesaving. Maintaining adequate breastfeeding, ensuring newborn bilirubin screening, and managing known hemolytic conditions are the cornerstones of prevention.

For the most up‑to‑date guidance, consult reputable sources such as the Mayo Clinic, the CDC, the NIH, the WHO, or your child’s pediatrician.

```